{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:10:56Z","timestamp":1791213056848,"version":"4.1.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Immunol"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1007\/s10875-010-9432-3","type":"journal-article","created":{"date-parts":[[2010,6,22]],"date-time":"2010-06-22T03:23:26Z","timestamp":1277177006000},"page":"681-692","source":"Crossref","is-referenced-by-count":12,"title":["IL-2 Immunotherapy to Recently HIV-1 Infected Adults Maintains the Numbers of IL-17 Expressing CD4+ T (TH17) Cells in the Periphery"],"prefix":"10.1007","volume":"30","author":[{"given":"Lishomwa C.","family":"Ndhlovu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorrie","family":"Epling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi Xuan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aashish R.","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ijeoma","family":"Eccles-James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Tincati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay A.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas F.","family":"Nixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick M.","family":"Hecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Barbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,6,23]]},"reference":[{"key":"9432_CR1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nm1585","volume":"13","author":"A Amadi-Obi","year":"2007","unstructured":"Amadi-Obi A, Yu CR, Liu X, Mahdi RM, Clarke GL, Nussenblatt RB, et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27\/STAT1. Nat Med. 2007;13:711\u20138.","journal-title":"Nat Med"},{"key":"9432_CR2","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.4049\/jimmunol.179.3.1423","volume":"179","author":"I Kryczek","year":"2007","unstructured":"Kryczek I, Wei S, Vatan L, Escara-Wilke J, Szeliga W, Keller ET, et al. Cutting edge: opposite effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated suppression. J Immunol. 2007;179:1423\u20136.","journal-title":"J Immunol"},{"key":"9432_CR3","doi-asserted-by":"crossref","first-page":"6730","DOI":"10.4049\/jimmunol.178.11.6730","volume":"178","author":"I Kryczek","year":"2007","unstructured":"Kryczek I, Wei S, Zou L, Altuwaijri S, Szeliga W, Kolls J, et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol. 2007;178:6730\u20133.","journal-title":"J Immunol"},{"key":"9432_CR4","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/QAD.0b013e3282ff884e","volume":"22","author":"LC Ndhlovu","year":"2008","unstructured":"Ndhlovu LC, Chapman JM, Jha AR, Snyder-Cappione JE, Pagan M, Leal FE, et al. Suppression of HIV-1 plasma viral load below detection preserves IL-17 producing T cells in HIV-1 infection. Aids. 2008;22:990\u20132.","journal-title":"Aids"},{"key":"9432_CR5","doi-asserted-by":"crossref","first-page":"6767","DOI":"10.1128\/JVI.02550-07","volume":"82","author":"FY Yue","year":"2008","unstructured":"Yue FY, Merchant A, Kovacs CM, Loutfy M, Persad D, Ostrowski MA. Virus-specific interleukin-17-producing CD4+ T cells are detectable in early human immunodeficiency virus type 1 infection. J Virol. 2008;82:6767\u201371.","journal-title":"J Virol"},{"key":"9432_CR6","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/nature06764","volume":"452","author":"JD Milner","year":"2008","unstructured":"Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature. 2008;452:773\u20136.","journal-title":"Nature"},{"key":"9432_CR7","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1084\/jem.20072066","volume":"205","author":"L Steinman","year":"2008","unstructured":"Steinman L. A rush to judgment on Th17. J Exp Med. 2008;205:1517\u201322.","journal-title":"J Exp Med"},{"key":"9432_CR8","doi-asserted-by":"crossref","first-page":"e1000295","DOI":"10.1371\/journal.ppat.1000295","volume":"5","author":"D Favre","year":"2009","unstructured":"Favre D, Lederer S, Kanwar B, Ma ZM, Proll S, Kasakow Z, et al. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog. 2009;5:e1000295.","journal-title":"PLoS Pathog"},{"key":"9432_CR9","doi-asserted-by":"crossref","unstructured":"Prendergast A, Prado JG, Kang YH, Chen F, Riddell LA, Luzzi G, et al. HIV-1 infection is characterized by profound depletion of CD161+ Th17 cells and gradual decline in regulatory T cells. Aids. 24:491\u2013502.","DOI":"10.1097\/QAD.0b013e3283344895"},{"key":"9432_CR10","doi-asserted-by":"crossref","unstructured":"El Hed A, Khaitan A, Kozhaya L, Manel N, Daskalakis D, Borkowsky W, et al. Susceptibility of human Th17 cells to human immunodeficiency virus and their perturbation during infection. J Infect Dis. 201:843\u201354.","DOI":"10.1086\/651021"},{"key":"9432_CR11","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/mi.2008.35","volume":"1","author":"M Macal","year":"2008","unstructured":"Macal M, Sankaran S, Chun TW, Reay E, Flamm J, Prindiville TJ, et al. Effective CD4+ T-cell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with enhanced Th17 cells and polyfunctional HIV-specific T-cell responses. Mucosal Immunol. 2008;1:475\u201388.","journal-title":"Mucosal Immunol"},{"key":"9432_CR12","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/mi.2009.90","volume":"2","author":"M Kader","year":"2009","unstructured":"Kader M, Wang X, Piatak M, Lifson J, Roederer M, Veazey R, et al. Alpha4(+)beta7(hi)CD4(+) memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection. Mucosal Immunol. 2009;2:439\u201349.","journal-title":"Mucosal Immunol"},{"key":"9432_CR13","doi-asserted-by":"crossref","unstructured":"Brenchley JM, Paiardini M, Knox KS, Asher AI, Cervasi B, Asher TE, et al. Differential Th17 CD4 T cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 2008.","DOI":"10.1182\/blood-2008-05-159301"},{"key":"9432_CR14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.smim.2007.10.009","volume":"19","author":"SJ Aujla","year":"2007","unstructured":"Aujla SJ, Dubin PJ, Kolls JK. Th17 cells and mucosal host defense. Semin Immunol. 2007;19:377\u201382.","journal-title":"Semin Immunol"},{"key":"9432_CR15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nm1743","volume":"14","author":"M Raffatellu","year":"2008","unstructured":"Raffatellu M, Santos RL, Verhoeven DE, George MD, Wilson RP, Winter SE, et al. Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med. 2008;14:421\u20138.","journal-title":"Nat Med"},{"key":"9432_CR16","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.immuni.2007.02.009","volume":"26","author":"A Laurence","year":"2007","unstructured":"Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, Yao Z, et al. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity. 2007;26:371\u201381.","journal-title":"Immunity"},{"key":"9432_CR17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1086\/314831","volume":"180","author":"A Arno","year":"1999","unstructured":"Arno A, Ruiz L, Juan M, Jou A, Balague M, Zayat MK, et al. Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with <\/=250\/microL CD4 T cells and undetectable plasma virus load. J Infect Dis. 1999;180:56\u201360.","journal-title":"J Infect Dis"},{"key":"9432_CR18","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1097\/00002030-200210180-00007","volume":"16","author":"C Katlama","year":"2002","unstructured":"Katlama C, Carcelain G, Duvivier C, Chouquet C, Tubiana R, De Sa M, et al. Interleukin-2 accelerates CD4 cell reconstitution in HIV-infected patients with severe immunosuppression despite highly active antiretroviral therapy: the ILSTIM study\u2013ANRS 082. Aids. 2002;16:2027\u201334.","journal-title":"Aids"},{"key":"9432_CR19","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1182\/blood-2003-09-3283","volume":"103","author":"CE Farel","year":"2004","unstructured":"Farel CE, Chaitt DG, Hahn BK, Tavel JA, Kovacs JA, Polis MA, et al. Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. Blood. 2004;103:3282\u20136.","journal-title":"Blood"},{"key":"9432_CR20","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1086\/342479","volume":"186","author":"G Marchetti","year":"2002","unstructured":"Marchetti G, Meroni L, Varchetta S, Terzieva V, Bandera A, Manganaro D, et al. Low-dose prolonged intermittent interleukin-2 adjuvant therapy: results of a randomized trial among human immunodeficiency virus-positive patients with advanced immune impairment. J Infect Dis. 2002;186:606\u201316.","journal-title":"J Infect Dis"},{"key":"9432_CR21","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1086\/318824","volume":"183","author":"D David","year":"2001","unstructured":"David D, Nait-Ighil L, Dupont B, Maral J, Gachot B, Theze J. Rapid effect of interleukin-2 therapy in human immunodeficiency virus-infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment. J Infect Dis. 2001;183:730\u20135.","journal-title":"J Infect Dis"},{"key":"9432_CR22","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1086\/513971","volume":"175","author":"RT Davey Jr","year":"1997","unstructured":"Davey Jr RT, Chaitt DG, Piscitelli SC, Wells M, Kovacs JA, Walker RE, et al. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J Infect Dis. 1997;175:781\u20139.","journal-title":"J Infect Dis"},{"key":"9432_CR23","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1172\/JCI119819","volume":"100","author":"P Paoli De","year":"1997","unstructured":"De Paoli P, Zanussi S, Simonelli C, Bortolin MT, D'Andrea M, Crepaldi C, et al. Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects. J Clin Invest. 1997;100:2737\u201343.","journal-title":"J Clin Invest"},{"key":"9432_CR24","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1086\/315736","volume":"182","author":"S Emery","year":"2000","unstructured":"Emery S, Capra WB, Cooper DA, Mitsuyasu RT, Kovacs JA, Vig P, et al. Pooled analysis of 3 randomized, controlled trials of interleukin-2 therapy in adult human immunodeficiency virus type 1 disease. J Infect Dis. 2000;182:428\u201334.","journal-title":"J Infect Dis"},{"key":"9432_CR25","doi-asserted-by":"crossref","first-page":"F225","DOI":"10.1097\/00002030-199817000-00003","volume":"12","author":"UR Hengge","year":"1998","unstructured":"Hengge UR, Goos M, Esser S, Exner V, Dotterer H, Wiehler H, et al. Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients. Aids. 1998;12:F225\u201334.","journal-title":"Aids"},{"key":"9432_CR26","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM199610313351803","volume":"335","author":"JA Kovacs","year":"1996","unstructured":"Kovacs JA, Vogel S, Albert JM, Falloon J, Davey Jr RT, Walker RE, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med. 1996;335:1350\u20136.","journal-title":"N Engl J Med"},{"key":"9432_CR27","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJM199503023320904","volume":"332","author":"JA Kovacs","year":"1995","unstructured":"Kovacs JA, Baseler M, Dewar RJ, Vogel S, Davey Jr RT, Falloon J, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med. 1995;332:567\u201375.","journal-title":"N Engl J Med"},{"key":"9432_CR28","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1080\/003655400750045259","volume":"32","author":"CS Larsen","year":"2000","unstructured":"Larsen CS, Ostergard L, Moller BK, Buhl MR. Subcutaneous interleukin-2 in combination with anti-retroviral therapy for treatment of HIV-1-infected subjects. Scand J Infect Dis. 2000;32:153\u201360.","journal-title":"Scand J Infect Dis"},{"key":"9432_CR29","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1365-2796.1998.00365.x","volume":"244","author":"O Witzke","year":"1998","unstructured":"Witzke O, Winterhagen T, Reinhardt W, Heemann U, Grosse-Wilde H, Kreuzfelder E, et al. Comparison between subcutaneous and intravenous interleukin-2 treatment in HIV disease. J Intern Med. 1998;244:235\u201340.","journal-title":"J Intern Med"},{"key":"9432_CR30","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/00002030-200302140-00008","volume":"17","author":"Y Levy","year":"2003","unstructured":"Levy Y, Durier C, Krzysiek R, Rabian C, Capitant C, Lascaux AS, et al. Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. Aids. 2003;17:343\u201351.","journal-title":"Aids"},{"key":"9432_CR31","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1128\/JVI.78.5.2454-2459.2004","volume":"78","author":"EM Aandahl","year":"2004","unstructured":"Aandahl EM, Michaelsson J, Moretto WJ, Hecht FM, Nixon DF. Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol. 2004;78:2454\u20139.","journal-title":"J Virol"},{"key":"9432_CR32","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1084\/jem.20032069","volume":"200","author":"AL Kinter","year":"2004","unstructured":"Kinter AL, Hennessey M, Bell A, Kern S, Lin Y, Daucher M, et al. CD25(+)CD4(+) regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4(+) and CD8(+) HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status. J Exp Med. 2004;200:331\u201343.","journal-title":"J Exp Med"},{"key":"9432_CR33","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.4049\/jimmunol.174.7.4407","volume":"174","author":"MP Eggena","year":"2005","unstructured":"Eggena MP, Barugahare B, Jones N, Okello M, Mutalya S, Kityo C, et al. Depletion of regulatory T cells in HIV infection is associated with immune activation. J Immunol. 2005;174:4407\u201314.","journal-title":"J Immunol"},{"key":"9432_CR34","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1189\/jlb.0507281","volume":"83","author":"LC Ndhlovu","year":"2008","unstructured":"Ndhlovu LC, Loo CP, Spotts G, Nixon DF, Hecht FM. FOXP3 expressing CD127lo CD4+ T cells inversely correlate with CD38+ CD8+ T cell activation levels in primary HIV-1 infection. J Leukoc Biol. 2008;83:254\u201362.","journal-title":"J Leukoc Biol"},{"key":"9432_CR35","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.4049\/jimmunol.174.6.3143","volume":"174","author":"J Andersson","year":"2005","unstructured":"Andersson J, Boasso A, Nilsson J, Zhang R, Shire NJ, Lindback S, et al. The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients. J Immunol. 2005;174:3143\u20137.","journal-title":"J Immunol"},{"key":"9432_CR36","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.4049\/jimmunol.174.4.1913","volume":"174","author":"J Nacsa","year":"2005","unstructured":"Nacsa J, Edghill-Smith Y, Tsai WP, Venzon D, Tryniszewska E, Hryniewicz A, et al. Contrasting effects of low-dose IL-2 on vaccine-boosted simian immunodeficiency virus (SIV)-specific CD4+ and CD8+ T cells in macaques chronically infected with SIVmac251. J Immunol. 2005;174:1913\u201321.","journal-title":"J Immunol"},{"key":"9432_CR37","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1086\/315430","volume":"181","author":"MH Losso","year":"2000","unstructured":"Losso MH, Belloso WH, Emery S, Benetucci JA, Cahn PE, Lasala MC, et al. A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >\/=350\/mm3. J Infect Dis. 2000;181:1614\u201321.","journal-title":"J Infect Dis"},{"key":"9432_CR38","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1001\/jama.284.2.183","volume":"284","author":"RT Davey Jr","year":"2000","unstructured":"Davey Jr RT, Murphy RL, Graziano FM, Boswell SL, Pavia AT, Cancio M, et al. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: a randomized controlled trial. Jama. 2000;284:183\u20139.","journal-title":"Jama"},{"key":"9432_CR39","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1086\/520087","volume":"196","author":"I Sereti","year":"2007","unstructured":"Sereti I, Sklar P, Ramchandani MS, Read SW, Aggarwal V, Imamichi H, et al. CD4+ T cell responses to interleukin-2 administration in HIV-infected patients are directly related to the baseline level of immune activation. J Infect Dis. 2007;196:677\u201383.","journal-title":"J Infect Dis"},{"key":"9432_CR40","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJMoa0903175","volume":"361","author":"D Abrams","year":"2009","unstructured":"Abrams D, Levy Y, Losso MH, Babiker A, Collins G, Cooper DA, et al. Interleukin-2 therapy in patients with HIV infection. N Engl J Med. 2009;361:1548\u201359.","journal-title":"N Engl J Med"},{"key":"9432_CR41","doi-asserted-by":"crossref","unstructured":"Sellier P, Lafuente-Lafuente C, Bergmann JF. Interleukin-2 therapy in patients with HIV infection. N Engl J Med. 362:270-1; author reply 271.","DOI":"10.1056\/NEJMc0910951"},{"key":"9432_CR42","doi-asserted-by":"crossref","unstructured":"Tincati C, Meroni L, Bellistri G, et al. Effects of immunoadjuvant therapy with IL-2 in HIV-positive HAART-naive patients in advanced stage of disease: a characterization of the divere immunological responses to IL-2. 11th European AIDS Conference\/European AIDS Clinical Society. Madrid, 2007.","DOI":"10.1186\/1758-2652-11-S1-P1"},{"key":"9432_CR43","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/QAD.0b013e32831cc114","volume":"23","author":"BO Porter","year":"2009","unstructured":"Porter BO, Anthony KB, Shen J, Hahn B, Keh CE, Maldarelli F, et al. Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial. Aids. 2009;23:203\u201312.","journal-title":"Aids"},{"key":"9432_CR44","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/01.qai.0000223027.47456.d0","volume":"42","author":"SW Read","year":"2006","unstructured":"Read SW, Higgins J, Metcalf JA, Stevens RA, Rupert A, Nason MC, et al. Decreased CD127 expression on T Cells in HIV-1-infected adults receiving antiretroviral therapy with or without intermittent IL-2 therapy. J Acquir Immune Defic Syndr. 2006;42:537\u201344.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"9432_CR45","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1086\/346056","volume":"187","author":"H Valdez","year":"2003","unstructured":"Valdez H, Mitsuyasu R, Landay A, Sevin AD, Chan ES, Spritzler J, et al. Interleukin-2 Increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s. J Infect Dis. 2003;187:320\u20135.","journal-title":"J Infect Dis"},{"key":"9432_CR46","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1046\/j.1365-2249.1999.01012.x","volume":"118","author":"N Imami","year":"1999","unstructured":"Imami N, Hardy GA, Nelson MR, Morris-Jones S, Al-Shahi R, Antonopoulos C, et al. Induction of HIV-1-specific T cell responses by administration of cytokines in late-stage patients receiving highly active anti-retroviral therapy. Clin Exp Immunol. 1999;118:78\u201386.","journal-title":"Clin Exp Immunol"},{"key":"9432_CR47","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/jmv.20675","volume":"78","author":"J Yu","year":"2006","unstructured":"Yu J, Chen H, Horton H, Bansal A, McElrath JM, Reichman R, et al. Interleukin-2 reconstitutes defective human immunodeficiency virus (HIV), and cytomegalovirus (CMV) specific CD8+ T cell proliferation in HIV infection. J Med Virol. 2006;78:1147\u201357.","journal-title":"J Med Virol"},{"key":"9432_CR48","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1086\/422036","volume":"190","author":"JD Barbour","year":"2004","unstructured":"Barbour JD, Hecht FM, Wrin T, Segal MR, Ramstead CA, Liegler TJ, et al. Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection. J Infect Dis. 2004;190:251\u20136.","journal-title":"J Infect Dis"},{"key":"9432_CR49","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/00126334-200308150-00012","volume":"33","author":"D Kothe","year":"2003","unstructured":"Kothe D, Byers RH, Caudill SP, Satten GA, Janssen RS, Hannon WH, et al. Performance characteristics of a new less sensitive HIV-1 enzyme immunoassay for use in estimating HIV seroincidence. J Acquir Immune Defic Syndr. 2003;33:625\u201334.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"9432_CR50","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1084\/jem.20060468","volume":"203","author":"N Seddiki","year":"2006","unstructured":"Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med. 2006;203:1693\u2013700.","journal-title":"J Exp Med"},{"key":"9432_CR51","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1084\/jem.20060772","volume":"203","author":"W Liu","year":"2006","unstructured":"Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med. 2006;203:1701\u201311.","journal-title":"J Exp Med"},{"key":"9432_CR52","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jim.2004.03.006","volume":"288","author":"DA Meiklejohn","year":"2004","unstructured":"Meiklejohn DA, Karlsson RK, Karlsson AC, Chapman JM, Nixon DF, Schweighardt B. ELISPOT cell rescue. J Immunol Methods. 2004;288:135\u201347.","journal-title":"J Immunol Methods"},{"key":"9432_CR53","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12026-007-8014-9","volume":"41","author":"Z Chen","year":"2008","unstructured":"Chen Z, O'Shea JJ. Th17 cells: a new fate for differentiating helper T cells. Immunol Res. 2008;41:87\u2013102.","journal-title":"Immunol Res"},{"key":"9432_CR54","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1038\/ni1467","volume":"8","author":"EV Acosta-Rodriguez","year":"2007","unstructured":"Acosta-Rodriguez EV, Rivino L, Geginat J, Jarrossay D, Gattorno M, Lanzavecchia A, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol. 2007;8:639\u201346.","journal-title":"Nat Immunol"},{"key":"9432_CR55","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","volume":"126","author":"II Ivanov","year":"2006","unstructured":"Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126:1121\u201333.","journal-title":"Cell"},{"key":"9432_CR56","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1002\/art.22866","volume":"56","author":"Z Chen","year":"2007","unstructured":"Chen Z, Tato CM, Muul L, Laurence A, O'Shea JJ. Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum. 2007;56:2936\u201346.","journal-title":"Arthritis Rheum"},{"key":"9432_CR57","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri1032","volume":"3","author":"JA Bluestone","year":"2003","unstructured":"Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol. 2003;3:253\u20137.","journal-title":"Nat Rev Immunol"},{"key":"9432_CR58","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.immuni.2009.09.002","volume":"31","author":"X Hu","year":"2009","unstructured":"Hu X, Ivashkiv LB. Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity. 2009;31:539\u201350.","journal-title":"Immunity"},{"key":"9432_CR59","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/ni.1731","volume":"10","author":"MA Koch","year":"2009","unstructured":"Koch MA, Tucker-Heard G, Perdue NR, Killebrew JR, Urdahl KB, Campbell DJ. The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat Immunol. 2009;10:595\u2013602.","journal-title":"Nat Immunol"},{"key":"9432_CR60","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1172\/JCI24307","volume":"115","author":"I Sereti","year":"2005","unstructured":"Sereti I, Imamichi H, Natarajan V, Imamichi T, Ramchandani MS, Badralmaa Y, et al. In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients. J Clin Invest. 2005;115:1839\u201347.","journal-title":"J Clin Invest"},{"key":"9432_CR61","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.4049\/jimmunol.177.3.1416","volume":"177","author":"A Cruz","year":"2006","unstructured":"Cruz A, Khader SA, Torrado E, Fraga A, Pearl JE, Pedrosa J, et al. Cutting edge: IFN-gamma regulates the induction and expansion of IL-17-producing CD4 T cells during mycobacterial infection. J Immunol. 2006;177:1416\u201320.","journal-title":"J Immunol"},{"key":"9432_CR62","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ni1497","volume":"8","author":"NJ Wilson","year":"2007","unstructured":"Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007;8:950\u20137.","journal-title":"Nat Immunol"}],"container-title":["Journal of Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10875-010-9432-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T04:48:07Z","timestamp":1559191687000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10875-010-9432-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,23]]},"references-count":62,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["9432"],"URL":"https:\/\/doi.org\/10.1007\/s10875-010-9432-3","relation":{},"ISSN":["0271-9142","1573-2592"],"issn-type":[{"value":"0271-9142","type":"print"},{"value":"1573-2592","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,23]]}}}